Following limited reports of adverse events encountered by US physicians using a particular batch of Healon D viscoelastic, AMO has recalled the remaining products in the batch.

Ellex's 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting.

A Phase I trial of POT-4, a complement inhibitor in development for the treatment of age-related macular degeneration (AMD), have demonstrated that the agent is safe and well tolerated. The results were presented by Potentia Pharmaceuticals during the Retina Subspecialty Day at the meeting of the American Academy of Ophthalmology.

The level of reimbursement of Optonol's Ex-PRESS Mini Glaucoma Shunt has been increased by the US Centers for Medicare and Medicaid (CMS), according to an announcement made by Optonol at the Glaucoma Subspecialty Day of this year's meeting of the American Academy of Ophthalmology.

Four new ophthalmic lasers and delivery devices have been unveiled by Lumenis at the meeting of the American Academy of Ophthalmology.

The Lamellar Corneal Surgery Module (LCS Module), with a hand-piece that can cut depths of 250?450 µm, has been released by Ziemer Group.

The Implantable Miniature Telescope (IMT) from VisionCare for end-stage age-related macular degeneration (AMD) maintains best-corrected visual acuity (BCVA) improvements to two years, according to results published in the November edition of the American Journal of Ophthalmology.

The Latanoprost punctal plug drug delivery system (L-PPDS) has performed well in its Phase II CORE trial, according to study data released by the manufacturer, QLT Plug Delivery Inc.

Following the conclusion of the five-year extension of their agreement, Carl Zeiss Meditech has acquired all manufacturing assets from Welch Allyn of their glaucoma diagnostic products, including the Humphrey FDT Visual Field Instrument.